- Home
- GORV vs SNGX Comparison
GORV vs SNGX Comparison
Compare GORV & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- SNGX
- Stock Information
- Founded
- GORV 1976
- SNGX 1987
- Country
- GORV United States
- SNGX United States
- Employees
- GORV N/A
- SNGX N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- SNGX Health Care
- Exchange
- GORV Nasdaq
- SNGX Nasdaq
- Market Cap
- GORV 10.6M
- SNGX 10.1M
- IPO Year
- GORV 2015
- SNGX 1987
- Fundamental
- Price
- GORV $3.06
- SNGX $2.79
- Analyst Decision
- GORV
- SNGX Strong Buy
- Analyst Count
- GORV 0
- SNGX 1
- Target Price
- GORV N/A
- SNGX $6.00
- AVG Volume (30 Days)
- GORV 950.5K
- SNGX 871.1K
- Earning Date
- GORV 08-14-2025
- SNGX 11-07-2025
- Dividend Yield
- GORV N/A
- SNGX N/A
- EPS Growth
- GORV N/A
- SNGX N/A
- EPS
- GORV N/A
- SNGX N/A
- Revenue
- GORV $662,952,000.00
- SNGX N/A
- Revenue This Year
- GORV $15.65
- SNGX N/A
- Revenue Next Year
- GORV $20.54
- SNGX N/A
- P/E Ratio
- GORV N/A
- SNGX N/A
- Revenue Growth
- GORV N/A
- SNGX N/A
- 52 Week Low
- GORV $2.22
- SNGX $1.09
- 52 Week High
- GORV $58.80
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- GORV 43.41
- SNGX 49.04
- Support Level
- GORV $2.30
- SNGX $2.58
- Resistance Level
- GORV $2.89
- SNGX $2.98
- Average True Range (ATR)
- GORV 0.60
- SNGX 0.20
- MACD
- GORV 0.08
- SNGX -0.08
- Stochastic Oscillator
- GORV 18.67
- SNGX 32.81
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).